Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2016 - 2025)

Ultragenyx Pharmaceutical has reported Long-Term Investments over the past 11 years, most recently at $57.0 million for Q4 2025.

  • Quarterly Long-Term Investments fell 57.78% to $57.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.0 million through Dec 2025, down 57.78% year-over-year, with the annual reading at $57.0 million for FY2025, 57.78% down from the prior year.
  • Long-Term Investments was $57.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $22.1 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $215.5 million in Q1 2022 and troughed at $2.8 million in Q4 2022.
  • The 5-year median for Long-Term Investments is $83.6 million (2023), against an average of $98.1 million.
  • Year-over-year, Long-Term Investments soared 4113.48% in 2024 and then crashed 89.13% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $18.5 million in 2021, then crashed by 84.83% to $2.8 million in 2022, then grew by 14.14% to $3.2 million in 2023, then soared by 4113.48% to $135.0 million in 2024, then crashed by 57.78% to $57.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Long-Term Investments are $57.0 million (Q4 2025), $22.1 million (Q3 2025), and $51.5 million (Q2 2025).